Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience.

No abstract is available for this paper.

• Publication year

  1985

• Venue

  Reviews of Infectious Diseases

• Publication date

  1985-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/CLINIDS/7.SUPPLEMENT_3.S528PMID 3901217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin and gentamicin

  2005cited by this paper
• Therapy for lower respiratory tract infections with imipenem/cilastatin: a review of worldwide experience.

  1985cited by this paper
• Imipenem/cilastatin in the treatment of obstetric and gynecologic infections.

  1985cited by this paper
• Imipenem/cilastatin in the treatment of intraabdominal infections: a review of worldwide experience.

  1985cited by this paper
• Imipenem/cilastatin in the treatment of obstetric and gynecologic infections: a review of worldwide experience.

  1985cited by this paper
• A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactam

  1984cited by this paper
• Neurotoxicity of antibacterial agents

  1984cited by this paper
• Imipenem versus moxalactam in the treatment of serious infections

  1983cited by this paper
• Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans

  1983cited by this paper
• Comparative study of imipenem in severe infections.

  1983cited by this paper
• Safety and tolerance comparison of imipenem-cilastatin to cephalothin and cefazolin.

  1983cited by this paper
• Relative Efficacy of β-Lactam Antimicrobial Agents in Two Animal Models of Infections Involving Bacteroides fragilis

  1983cited by this paper
• Susceptibilities of anaerobic bacteria to N-formimidoyl thienamycin (MK0787) and to other antibiotics

  1982cited by this paper
• Comparative activities of N-formimidoyl thienamycin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia

  1982cited by this paper
• Effects of azlocillin in combination with clavulanic acid, sulbactam, and N-formimidoyl thienamycin against beta-lactamase-producing, carbenicillin-resistant Pseudomonas aeruginosa

  1982cited by this paper
• Superior activity of N-formimidoyl thienamycin against gentamicin-resistant Pseudomonas aeruginosa

  1981cited by this paper
• In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp

  1981cited by this paper
• N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics.

  1981cited by this paper
• The antibacterial activity of thienamycin against multiresistant bacteria-comparison with beta-lactamase stable compounds.

  1980cited by this paper
• Thienamycin: New Beta-Lactam Antibiotic with Potent Broad-Spectrum Activity

  1979cited by this paper
• Acute colitis related to penicillin and penicillin derivatives.

  1978cited by this paper
• Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms.

  1977cited by this paper
• Diarrhea associated with clindamycin and ampicillin therapy: preliminary results of a cooperative study.

  1977cited by this paper

• Simultaneous electrochemical detection of imipenem and meropenem using a Pt-Au bimetallic nanoparticle-decorated 3D graphene oxide modified glassy carbon electrode.

  2026cites this paper
• A minimally invasive lateral approach with CT navigation for open biopsy and diagnosis of Nocardia nova L4–5 discitis osteomyelitis: illustrative case

  2021cites this paper
• A novel analytical method to assess the effect of imipenem/cilastatin on liver function laboratory indexes in Chinese underage inpatients: Probability distribution curve

  2019cites this paper
• Imipenem toxicity in male reproductive organs as a result of inflammatory microenvironment and oxidative stress in germinal cells.

  2019cites this paper
• A novel reversed‐phase high‐performance liquid chromatographic assay for the simultaneous determination of imipenem and meropenem in human plasma and its application in TDM

  2019cites this paper
• Characterisation and directed evolution of novel metallo-β-lactamases - spr-1 and aim-1

  2014influential citation
• The risk of seizures among the carbapenems: a meta-analysis.

  2014cites this paper
• Economic Aspects of Antibacterial Adverse Effects

  2012cites this paper
• Imipenem/Cilastatin

  2012cites this paper
• An overview of harms associated with β-lactam antimicrobials: where do the carbapenems fit in?

  2008cites this paper
• Drug Use Evaluation of Carbapenem in Korean Hospitalized Patients

  2007cites this paper
• Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem.

  2007cites this paper
• Safety Profile of Meropenem

  2007cites this paper
• Carbapenems in the USA: focus on doripenem

  2007cites this paper
• Clinical Importance of Carbapenem Hypersensitivity in Patients with Self‐Reported and Documented Penicillin Allergy

  2007cites this paper
• Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections

  2005cites this paper
• Randomized multicenter clinical trial with imipenem/cilastatin versus cefotaxime/gentamicin in the treatment of patients with non-life-threatening infections

  2005cites this paper
• Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy.

  2004cites this paper
• Pharmacokinetics of imipenem in dogs.

  2003cites this paper
• Antimicrobial activity of imipenem against isolates from complicated urinary tract infections.

  2002cites this paper
• Seizures in the Critically Ill: The Role of Imipenem

  2001cites this paper
• Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.

  2000cites this paper
• Meropenem

  2000cites this paper
• IgE‐mediated anaphylactic reaction to imipenem

  2000cites this paper
• Meropenem: an updated review of its use in the management of intra-abdominal infections.

  2000cites this paper
• INCIDENCE OF SEIZURES IN PEDIATRIC CANCER PATIENTS TREATED WITH IMIPENEM/CILASTATIN

  2000cites this paper
• Seizures and Commonly Prescribed Drugs

  1999cites this paper
• Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem.

  1999cites this paper
• Imipenem and meropenem

  1999cites this paper
• Meropenem

  1998cites this paper
• Antibiotic-induced convulsions.

  1997cites this paper
• Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections.

  1997cites this paper
• Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches.

  1997cites this paper
• A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes

  1997cites this paper
• Meropenem: evaluation of a new generation carbapenem.

  1997cites this paper
• Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

  1996cites this paper
• Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.

  1996cites this paper
• Carbapenems.

  1995cites this paper
• Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.

  1995cites this paper
• Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem.

  1995cites this paper
• The newer cephalosporins. Aztreonam and imipenem.

  1995cites this paper
• New antimicrobial agents.

  1995cites this paper
• Emergence of multidrug-resistant isolates of Acinetobacter baumannii.

  1994cites this paper
• A prospective randomized trial of imipenem-cilastatin versus clindamycin/tobramycin in the treatment of intra-abdominal and pelvic infections.

  1993cites this paper
• Imipenem-cilastatin for the treatment of bacterial complications in the immunocompromised host

  1992cites this paper
• Intramuscular imipenem/cilastatin in multiple-dose treatment regimens: review of the worldwide clinical experience.

  1991cites this paper
• Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis.

  1991cites this paper
• In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I

  1991cites this paper
• Treatment of nosocomial infections in children undergoing antimicrobial chemotherapy

  1990cites this paper
• Pharmacokinetic studies in animals of a new parenteral penem CP-65,207 and its oral prodrug ester.

  1990cites this paper
• Seizure Activity with Imipenem Therapy: Incidence and Risk Factors

  1990cites this paper
• Imipenem-antibiotic monotherapy in juvenile cancer patients with neutropenia.

  1990cites this paper
• Imipenem/cilastatin treatment of acute infections in AIDS/ARC patients.

  1990cites this paper
• The carbapenems and penem antibiotics—a brief review

  1990cites this paper
• [An imipenem-cilastatin combination in the treatment of infection at general intensive care units].

  1990cites this paper
• Imipenem-cilastatin in pediatric patients: an overview of safety and efficacy in studies conducted in the United States.

  1989cites this paper
• Cilastatin-insulin interaction in the rat.

  1989cites this paper
• In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338

  1989cites this paper
• The microbiology and chemotherapy of odontogenic infections.

  1989cites this paper
• The Efficacy Results and Safety Profile of Imipenem/Cilastatin from the Clinical Research Trials

  1988cites this paper
• Successful treatment of recurrent cerebral empyema and brain abscesses with Imipenem

  1987cites this paper
• Imipenem/cilastatin therapy for serious infections in neonates and infants.

  1987cites this paper
• Intramuscular imipenem/cilastatin in the treatment of mild and moderate infections.

  1987cites this paper
• Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.

  1987cites this paper
• Problems and benefits of an antibiotic compassionate therapy program.

  1987cites this paper
• Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetics.

  1987cites this paper
• Efficacy and safety of imipenem/cilastatin in the empirical treatment of septicemia.

  1987cites this paper
• Imipenem/cilastatin for pediatric infections in hospitalized patients.

  1987cites this paper
• Imipenem and cilastatin in acute osteomyelitis and suppurative arthritis. Therapy in infants and children.

  1987cites this paper
• Imipenem/Cilastatin: Monotherapy of Hospital Infections

  1987cites this paper
• Chapter 12. Antimicrobial Drugs – Clinical Problems and Opportunities

  1986cites this paper
• Imipenem-cilastatin: the first thienamycin antibiotic.

  1986cites this paper
• In vitro and pharmacokinetic properties of the carbapenems

  1986cites this paper
• Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa

  1986cites this paper
• Imipenem: the first thienamycin antibiotic.

  1986cites this paper
• The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients.

  1986cites this paper
• Wirksamkeit und Verträglichkeit von Imipenem/Cilastatin bei der Behandlung chirurgischer Infektionen mit und ohne Knochenbeteiligung

  1986influential citation
• [Treatment of respiratory tract infections with imipenem/cilastatin in critical patients with respiratory insufficiency].

  1986cites this paper
• Ecological Impacts of Antibacterial Agents: Stockholm, March 7–8, 1986

  1986cites this paper
• Imipenem/cilastatin: a multicentre international study of its clinical efficacy, safety and potential as empirical therapy.

  1986cites this paper
• Problems in evaluation of adverse reactions to beta-lactam antibiotics.

  1986cites this paper
• Newer antibiotics for the surgeon

  1986cites this paper
• [Efficacy and tolerance of imipenem/cilastatin in the treatment of surgical infections with and without bone involvement].

  1986cites this paper
• Clinical Pharmacology of Antibiotics: Review of Imipenem

  1986influential citation
• Thomas G. Orr memorial lecture. Newer antibiotics for the surgeon.

  1986cites this paper
• Imipenem: first of a new class of beta-lactam antibiotics.

  1985cites this paper
• Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin.

  1985cites this paper